摘要
t(8;21)(q22;q22)是急性髓系白血病(acute myeloid leukemia,AML)中最常见的染色体易位,其易位产生AML1-ETO融合基因。AML1-ETO阳性AML通常被认为是预后较好的白血病类型,但只有一部分患者可用目前方法治愈。AML1-ETO阳性AML是一类异质性很大的疾病,复发难治的原因尚不明确,近年来其预后相关研究有了很大的进展。本文就细胞遗传学异常、基因突变、表观遗传学改变和治疗等方面因素对预后的影响做一综述。
The t(8;21)(q22;q22) is the most common chromosomal translocation in acute myeloid leukemia(AML), and this translocation forms AML1-ETO fusion gene. AML with AML1-ETO gene positive is generally considered a better prognosis type of leukemias, but is available cured for some patients currently. AML with AML1-ETO gene positive is a large class of heterogeneity diseases, which reasons of relapsed or refractory are not yet clear. In recent years, studies about the prognosis reaearch have been much progress. In this article, the patient's age, white blood cell count, cytogenetic abnormalities, genetic mutations, epigenetic changes and treatment strategies affecting the prognosis are summarized.
出处
《临床检验杂志（电子版）》
2015年第3期916-924,共9页
Clinical Laboratory Journal(Electronic Edition)
